Rapid Medical Ltd. has secured United States Food and Drug Administration 510(k) clearance for DRIVEWIRE 35, a steerable 0.035-inch guidewire intended to facilitate catheter placement in neurovascular and peripheral vascular procedures. The privately held medical device company also reported the first clinical cases involving the guidewire, including its use during treatment of an intracranial occlusion.
The clearance, announced on July 21, 2026, at the Society of NeuroInterventional Surgery’s 23rd Annual Meeting and Fellows Course, extends Rapid Medical’s steerable access technology into a larger guidewire format. The company is initially emphasising stroke procedures, where tortuous anatomy and delays in advancing catheters can complicate the path to a blocked vessel.
However, the commercial and clinical significance of DRIVEWIRE 35 will depend on more than its steerable design. The first cases demonstrate technical feasibility in selected procedures, but they do not yet establish that the device consistently reduces access time, lowers the number of devices required or improves patient outcomes.
What exactly did the FDA clear DRIVEWIRE 35 to do in neurovascular procedures?
The United States Food and Drug Administration recorded DRIVEWIRE 35 under 510(k) number K254006 and issued its substantial-equivalence decision on July 17, 2026. The submission was received on December 15, 2025 and followed the traditional 510(k) pathway without third-party review.
The device is classified as a Class II catheter guidewire under regulation 21 CFR 870.1330, with the review assigned to the neurology panel. Rapid Medical said the clearance covers neurovascular and peripheral vascular access, with DRIVEWIRE 35 intended to assist physicians in selectively positioning compatible diagnostic or therapeutic catheters.
That wording matters. DRIVEWIRE 35 is an access device rather than a thrombectomy device that independently captures or removes a clot. Its role is to help physicians navigate a catheter toward the treatment site, after which another device or technique may be used to treat the underlying vascular condition.
The clearance therefore does not establish that DRIVEWIRE 35 improves stroke outcomes, shortens procedure time or performs better than conventional guidewires. A 510(k) decision means the regulator found the device substantially equivalent to an appropriate legally marketed device for the stated intended use. It is clearance to market the guidewire within its label, not a clinical endorsement of every potential workflow advantage described by the company.
How does active steering differentiate DRIVEWIRE 35 from conventional guidewire navigation?
Conventional guidewires generally depend on a combination of preset tip shape, torque transmission and physician manipulation. Operators rotate and advance the wire while using fluoroscopic imaging to follow its movement through blood vessels and guide a catheter along the desired pathway.
DRIVEWIRE 35 adds controlled tip deflection. Rapid Medical said physicians can reshape and redirect the wire while it is inside the vessel, allowing the wire to provide active steering to a compatible catheter. By changing the orientation of the guidewire tip, the operator may be able to direct the catheter into a selected vessel or around a difficult anatomical turn without repeatedly withdrawing the wire for manual reshaping.
The 0.035-inch format is commercially important because it moves the steerable concept into a size widely associated with larger vascular access platforms. Rapid Medical said the device combines tip control with distal support, potentially allowing physicians to articulate a compatible catheter rather than relying on several telescoped wires and catheters to negotiate difficult anatomy.
This does not make every catheter steerable in an unrestricted sense. Performance will depend on compatibility, vessel anatomy, the catheter being advanced, friction within the system and the operator’s familiarity with the guidewire’s control mechanism. The value proposition is therefore procedural rather than simply mechanical: the device must show that its additional control solves real access problems without introducing unnecessary complexity.
What do the first reported stroke cases establish about DRIVEWIRE 35 performance?
Jeremy Rempel of the University of Alberta Hospital in Edmonton performed what Rapid Medical described as the first clinical cases worldwide. In one reported case, the guidewire was used to help navigate catheters during treatment of an intracranial occlusion without advancing the wire through the clot.
Rempel indicated that the ability to shape the wire inside the vessel helped him direct the catheter toward the occlusion, navigate around vessel edges and address the ledge effect. He also suggested that the combination of steering and support could reduce reliance on additional access devices in some procedures.
These observations are clinically relevant because they describe how the product may be used in an actual neurointerventional workflow. They are not, however, equivalent to a prospective clinical study. Rapid Medical did not disclose a formal case series, patient number, comparator group, procedure-time analysis or detailed safety dataset for the first DRIVEWIRE 35 cases.
The announcement also did not provide quantitative measurements such as time from arterial puncture to target-vessel access, fluoroscopy duration, contrast use, number of catheter exchanges, vessel injury or final neurological outcome. The cases consequently support the feasibility of the steering concept but cannot determine whether it delivers a repeatable advantage over established guidewires.
The location of the procedures is another useful distinction. The first reported cases were performed in Canada, while the regulatory development concerns United States clearance. They demonstrate clinical use, but they should not be interpreted as evidence of broad United States hospital adoption or a completed American commercial rollout.
Why can difficult vascular anatomy become a major obstacle during stroke thrombectomy?
Mechanical thrombectomy is highly time-sensitive, but reaching an intracranial occlusion can be difficult in patients with tortuous aortic arches, sharply angled vessels, elongated arteries or other anatomical variations. Even when imaging confirms that a patient is eligible for treatment, challenging access may delay the stage at which the clot-removal device can be deployed.
The ledge effect can arise when the edge of a catheter encounters a vessel wall, branch or anatomical transition instead of following the guidewire smoothly. Operators may respond by changing the wire, altering the catheter combination or adding another intermediate device. Each adjustment may consume time and add procedural steps.
DRIVEWIRE 35 is designed to address this access phase. If controlled tip deflection enables a catheter to follow the intended path more predictably, the guidewire could reduce repeated manipulation or the need to assemble more complex nested systems. That is the operational logic behind Rapid Medical’s claim that active steering may streamline access.
Yet the most commercially persuasive evidence would involve measurable performance across varied anatomies and operators. A guidewire that helps in an unusually difficult case may be valuable, but hospitals will want to know how often that situation occurs, whether the device consistently changes the procedure and whether its benefits justify training and acquisition costs.
How much does the experience with DRIVEWIRE 24 support the larger guidewire platform?
Rapid Medical said DRIVEWIRE 24 has been used in nearly 5,000 procedures. That experience gives the company an installed base of physicians familiar with its steerable-access concept and may reduce the educational burden associated with introducing DRIVEWIRE 35.
The United States Food and Drug Administration cleared DRIVEWIRE 24 in July 2024 under 510(k) number K233791. The 0.024-inch guidewire was cleared for general intravascular use, including the neurovascular and peripheral vasculature, to facilitate selective placement of diagnostic or therapeutic catheters. It was not intended for coronary use.
The regulatory summary for DRIVEWIRE 24 described a steerable tip controlled through a handle, a hydrophilic distal segment and radiopaque characteristics intended to support fluoroscopic navigation. Its clearance was supported by non-clinical bench testing, biocompatibility work, simulated-use testing and an animal study. No clinical study was conducted for that submission because substantial equivalence was established through the non-clinical package.
Nearly 5,000 DRIVEWIRE 24 cases may indicate growing physician exposure, but utilisation is not the same as evidence of superior outcomes. It does not automatically establish that DRIVEWIRE 35 will produce the same handling characteristics, safety profile or workflow value. The larger diameter changes its relationship with compatible catheters and may position it for different parts of the access procedure.
The earlier product nevertheless provides Rapid Medical with more than a standing start. Physicians already using DRIVEWIRE 24 could become the first adopters of DRIVEWIRE 35, particularly if they have encountered situations where a larger guidewire could provide additional support.
What will hospitals examine before adding DRIVEWIRE 35 to stroke procedure inventories?
Unlike a large capital system, a guidewire does not require a hospital to install expensive equipment. Adoption can still involve a structured evaluation by neurointerventional specialists, supply-chain teams and value-analysis committees.
Hospitals will need clarity on catheter compatibility, packaging, sterilisation, shelf life, storage requirements, pricing and product availability. They may also examine whether DRIVEWIRE 35 replaces an existing wire, reduces the use of other access devices or is added as another item to an already complex procedure tray.
Training will be especially important because active tip deflection introduces a control behaviour that differs from conventional torque-based guidewire manipulation. Experienced neurointerventionalists may learn the system quickly, but performance could vary during the initial learning period. Hospitals will want protocols covering device preparation, fluoroscopic visibility, steering limits and appropriate responses if the wire or catheter does not advance as intended.
Safety surveillance will also matter. Guidewire manipulation inside the neurovasculature requires careful control because excessive force, unintended advancement or interaction with vessel walls can create procedural risk. The clearance establishes substantial equivalence for the labelled use, but broader clinical experience will be necessary to characterise performance across diverse anatomies and procedure types.
The strongest procurement argument would be evidence that the product reduces another identifiable cost or bottleneck. If DRIVEWIRE 35 lowers catheter exchanges, shortens access time or reduces reliance on additional devices, its economic case could extend beyond the purchase price of the guidewire itself.
Can DRIVEWIRE 35 strengthen Rapid Medical’s position across the stroke procedure pathway?
Rapid Medical’s portfolio includes TIGERTRIEVER thrombectomy devices, COMANECI adjustable devices for aneurysm procedures and the DRIVEWIRE access family. DRIVEWIRE 35 expands the company’s presence into another stage of neurovascular intervention, beginning with the route to the treatment site rather than only the treatment performed after access is achieved.
That positioning could support broader relationships with stroke centres. A company supplying tools for access, clot retrieval and other neurovascular procedures can potentially build deeper physician familiarity and a more integrated commercial offering. The strategy also allows Rapid Medical to apply its adjustable-device engineering across multiple procedural challenges.
DRIVEWIRE 35 is the third steerable guidewire in the company’s portfolio, according to Rapid Medical. Its larger size may also open opportunities outside stroke because the clearance encompasses peripheral vascular use. However, the announcement centred on stroke, and the company has not yet disclosed a detailed commercial plan for wider peripheral adoption.
Rapid Medical is privately held, so there is no public share-price reaction or market-capitalisation layer to assess. The more meaningful signals will be United States launch timing, the number of trained centres, repeat ordering, geographic expansion and any publication of procedure-level evidence.
What evidence would show whether DRIVEWIRE 35 genuinely improves stroke access?
Prospective real-world data could determine whether DRIVEWIRE 35 reduces time to target-vessel access compared with conventional guidewires in anatomically difficult cases. Useful endpoints would include the number of wire and catheter exchanges, need for rescue access techniques, fluoroscopy duration, contrast volume, procedural complications and successful catheter placement.
A broader comparative study could also examine whether any access advantage affects time to reperfusion. That would be more clinically meaningful, although patient outcomes in stroke are influenced by many factors beyond the guidewire, including occlusion location, collateral circulation, clot characteristics, imaging selection and the thrombectomy technique used after access is achieved.
Rapid Medical must therefore avoid allowing a logical procedural benefit to outrun the supporting evidence. Active steering may help physicians solve a genuine technical problem, but the current public evidence consists mainly of regulatory clearance, the company’s engineering description, experience with the smaller DRIVEWIRE 24 and a limited number of reported first cases.
The immediate achievement is regulatory and technical: Rapid Medical can bring a steerable 0.035-inch guidewire into the United States neurovascular and peripheral access market. The next test is whether hospitals and physicians can translate that steering capability into fewer access steps, reliably shorter procedures and a clear enough operational advantage to make DRIVEWIRE 35 a routinely stocked device rather than a specialised option for difficult anatomy.
